Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial

Chloe Orkin, Kathleen E Squires, Jean-Michel Molina, Paul E Sax, Otto Sussmann, Gina Lin, Sushma Kumar, George J Hanna, Carey Hwang, Elizabeth Martin, Hedy Teppler, Chloe Orkin, Kathleen E Squires, Jean-Michel Molina, Paul E Sax, Otto Sussmann, Gina Lin, Sushma Kumar, George J Hanna, Carey Hwang, Elizabeth Martin, Hedy Teppler

Abstract

Background: Doravirine (DOR) is a nonnucleoside reverse-transcriptase inhibitor. In the phase 3 DRIVE-AHEAD trial in treatment-naive adults with human immunodeficiency virus type 1 (HIV-1) infection, DOR demonstrated noninferior efficacy compared with efavirenz (EFV) and superior profiles for neuropsychiatric tolerability and lipids at 48 weeks. We present data through week 96.

Methods: DRIVE-AHEAD is a phase 3, multicenter, double-blind, noninferiority trial in antiretroviral treatment-naive adults with HIV-1 RNA ≥1000 copies/mL. Participants were randomized to a daily fixed-dose tablet of DOR (100 mg), lamivudine (3TC; 300 mg) and tenofovir disoproxil fumarate (TDF; 300 mg) (DOR/3TC/TDF) or EFV (600 mg), emtricitabine (FTC; 200 mg) and TDF (300 mg) (EFV/FTC/TDF). The efficacy end point of interest at week 96 was the proportion of participants with HIV-1 RNA levels <50 copies/mL (Food and Drug Administration Snapshot Approach) with a predefined noninferiority margin of 10% to support week 48 results. Safety end points of interest included prespecified neuropsychiatric adverse events and the mean change in fasting lipids at week 96.

Results: Of 734 participants randomized, 728 received study drugs and were included in analyses. At week 96, HIV-1 RNA <50 copies/mL was achieved by 77.5% of DOR/3TC/TDF vs 73.6% of EFV/FTC/TDF participants, with a treatment difference of 3.8% (95% confidence interval, -2.4% to 10%). Virologic failure rates were low and similar across treatment arms, with no additional resistance to DOR observed between weeks 48 and 96. Prespecified neuropsychiatric adverse events and rash were less frequent in DOR/3TC/TDF than in EFV/FTC/TDF participants through week 96. At week 96, fasting low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol (HDL-C) levels increased in the EFV/FTC/TDF group but not in the DOR/3TC/TDF group; the mean changes from baseline in total cholesterol/HDL-C ratio were similar.

Clinical trials registration: NCT02403674.

Keywords: HIV-1; NNRTI; doravirine; efavirenz; treatment-naive.

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Trial design. Abbreviations: 3TC, lamivudine; DOR, doravirine; EFV, efavirenz; FTC, emtricitabine; PBO, placebo; QD, once daily; TDF, tenofovir disoproxil fumarate.
Figure 2.
Figure 2.
Disposition of participants through week 96. Abbreviations: 3TC, lamivudine; DOR, doravirine; EFV, efavirenz; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate.
Figure 3.
Figure 3.
Proportion of participants with human immunodeficiency virus type 1 RNA level 

Figure 4.

Efficacy by subgroup (observed failure…

Figure 4.

Efficacy by subgroup (observed failure approach) at week 96. Abbreviations: 3TC, lamivudine; CI,…

Figure 4.
Efficacy by subgroup (observed failure approach) at week 96. Abbreviations: 3TC, lamivudine; CI, confidence interval; DOR, doravirine; EFV, efavirenz; FTC, emtricitabine; HBV, hepatitis B virus, HCV, hepatitis C virus; HIV-1, human immunodeficiency virus type 1; TDF, tenofovir disoproxil fumarate.

Figure 5.

Proportion of participants with neuropsychiatric…

Figure 5.

Proportion of participants with neuropsychiatric adverse events in prespecified categories through week 96.…

Figure 5.
Proportion of participants with neuropsychiatric adverse events in prespecified categories through week 96. Abbreviations: 3TC, lamivudine; CI, confidence interval; DOR, doravirine; EFV, efavirenz; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate. (Between-group difference calculated as follows: DOR – EFV.)

Figure 6.

Mean change in fasting lipid…

Figure 6.

Mean change in fasting lipid levels at week 96. Abbreviations: 3TC, lamivudine; CI,…

Figure 6.
Mean change in fasting lipid levels at week 96. Abbreviations: 3TC, lamivudine; CI, confidence interval; DOR, doravirine; EFV, efavirenz; FTC, emtricitabine; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non-HDL cholesterol; TDF, tenofovir disoproxil fumarate. (Between-group difference calculated as follows: DOR – EFV.)
Figure 4.
Figure 4.
Efficacy by subgroup (observed failure approach) at week 96. Abbreviations: 3TC, lamivudine; CI, confidence interval; DOR, doravirine; EFV, efavirenz; FTC, emtricitabine; HBV, hepatitis B virus, HCV, hepatitis C virus; HIV-1, human immunodeficiency virus type 1; TDF, tenofovir disoproxil fumarate.
Figure 5.
Figure 5.
Proportion of participants with neuropsychiatric adverse events in prespecified categories through week 96. Abbreviations: 3TC, lamivudine; CI, confidence interval; DOR, doravirine; EFV, efavirenz; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate. (Between-group difference calculated as follows: DOR – EFV.)
Figure 6.
Figure 6.
Mean change in fasting lipid levels at week 96. Abbreviations: 3TC, lamivudine; CI, confidence interval; DOR, doravirine; EFV, efavirenz; FTC, emtricitabine; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non-HDL cholesterol; TDF, tenofovir disoproxil fumarate. (Between-group difference calculated as follows: DOR – EFV.)

References

    1. Anderson MS, Gilmartin J, Cilissen C, et al. . Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects. Antivir Ther 2015; 20:397–405.
    1. Colombier MA, Molina JM. Doravirine: a review. Curr Opin HIV AIDS 2018; 13:308–14.
    1. Feng M, Sachs NA, Xu M, et al. . Doravirine suppresses common nonnucleoside reverse transcriptase inhibitor-associated mutants at clinically relevant concentrations. Antimicrob Agents Chemother 2016; 60:2241–7.
    1. Feng M, Wang D, Grobler JA, Hazuda DJ, Miller MD, Lai MT. In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways. Antimicrob Agents Chemother 2015; 59:590–8.
    1. Smith SJ, Pauly GT, Akram A, et al. . Rilpivirine and doravirine have complementary efficacies against NNRTI-resistant HIV-1 mutants. J Acquir Immune Defic Syndr 2016; 72:485–91.
    1. Behm MO, Yee KL, Liu R, Levine V, Panebianco D, Fackler P. The effect of food on doravirine bioavailability: results from two pharmacokinetic studies in healthy subjects. Clin Drug Investig 2017; 37:571–9.
    1. Wilby KJ, Eissa NA. Clinical pharmacokinetics and drug interactions of doravirine. Eur J Drug Metab Pharmacokinet 2018; 43:637–44.
    1. Deeks ED. Doravirine: first global approval. Drugs 2018; 78:1643–50.
    1. Molina JM, Squires K, Sax PE, et al. ; DRIVE-FORWARD Study Group . Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV 2018; 5:e211–20.
    1. Orkin C, Squires KE, Molina JM, et al. . Doravirine/lamivudine/tenofovir disoproxil fumarate is non-inferior to efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD trial. Clin Infect Dis 2019; 68:535–44.
    1. Division of AIDS, National Institute of Allergy and Infectious Disease Division of AIDS table for grading the severity of adult and pediatric adverse events. Bethesda, MD: National Institute of Allergy and Infectious Disease,2004.
    1. Nelson MR, Elion RA, Cohen CJ, et al. . Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE studies. HIV Clin Trials 2013; 14:81–91.
    1. Porter DP, Kulkarni R, Fralich T, Miller MD, White KL. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects. HIV Clin Trials 2015; 16:30–8.
    1. Dickinson L, Amin J, Else L, et al. . Comprehensive pharmacokinetic, pharmacodynamic and pharmacogenetic evaluation of once-daily efavirenz 400 and 600 mg in treatment-naïve HIV-infected patients at 96 weeks: results of the ENCORE1 Study. Clin Pharmacokinet 2016; 55:861–73.
    1. Walmsley S, Baumgarten A, Berenguer J, et al. . Brief report: dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial. J Acquir Immune Defic Syndr 2015; 70: 515–9.
    1. Cohen C, Wohl D, Arribas JR, et al. . Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. AIDS 2014; 28:989–97.
    1. Molina JM, Clotet B, van Lunzen J, et al. . Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO. J Int AIDS Soc 2014; 17:19490.
    1. Cahn P, Madero JS, Arribas JR, et al. ; GEMINI Study Team . Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet 2019; 393:143–55.
    1. Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. . Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med 2020; 382:1112–23.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться